Spinal Cord Stimulation Articles & Analysis
30 news found
Patent provides protection for High Frequency Spinal Cord Stimulation with Beat Technology Vancouver, Washington – March 20, 2015 – Meagan Medical Inc., a clinical research and medical device development company focused on investigating and developing optimal ways of managing and controlling pain, announced today ...
I believe Nalu’s unique system and technology, including the miniaturized, battery-free implantable pulse generator with its broad capabilities, upgradability and industry leading longevity are going to meaningfully expand the number of chronic pain patients who can benefit from both Spinal Cord and Peripheral Nerve Stimulation. Nalu is ...
Saluda Medical’s Evoke® System is the first and only available closed-loop spinal cord stimulation system to maintain consistent therapy through dynamic sensing technology that automatically senses and responds to the level of neural activation – more than 100+ times per second – to deliver long-term superior outcomes. ...
Announced positive five-year bench top results in stimulation testing of electrodes designed for use in spinal cord stimulation for patients suffering with chronic back pain. ...
Transformative closed-loop technology senses the spinal cord’s response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment Long-term results published in two premier clinical journals show clinically meaningful improvements in pain relief, physical and emotional functioning, sleep quality, and ...
The Company executed the first double-blind pivotal randomized controlled trial (RCT) in the history of spinal cord stimulation (SCS) that showed nearly 9 out 10 patients experience long-term pain relief and clinically meaningful improvements in quality of life, performing activities of daily living, sleep, mood and opioid reduction with zero ...
This update adds significant new capabilities for both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). The update broadens the stimulation pulse width parameter to the widest range currently available in implantable SCS and PNS systems—up to 2,000 microseconds. ...
The Company also expects to release long-term data in the near future on electrodes that would provide therapeutic stimulation for the same applications mentioned earlier. As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation, chronic stimulation use for DBS (deep brain ...
REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 12:30 pm Eastern ...
Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related Practices and Policies. REDWOOD CITY, Calif., Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has been named to the 2022 Bloomberg Gender-Equality Index (GEI). The ...
The trials presented by our competitor to support its FDA submission makes especially clear that our proprietary, paresthesia-free 10 kHz Therapy is uniquely suited to treat PDN patients. In fact, a recent review of spinal cord stimulation evidence for painful diabetic neuropathy concluded, 'High-frequency 10 kHz SCS offers several advantages ...
Company to Host Conference Call on Wednesday, February 23, 2022 at 1:30 pm PT / 4:30 pm ET. REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full-year ...
(NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced receipt of FDA approval for expanded labeling for its Senza® Spinal Cord Stimulation (SCS) System for the treatment of Non-Surgical Refractory Back Pain (NSRBP). ...
Both SENZA-PDN and SENZA-NSRBP Studies Demonstrated Cost Savings with 10 kHz Spinal Cord Stimulation in Healthcare Utilization at 12 Months. REDWOOD CITY, Calif., Jan. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, ...
Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million. Full-Year 2021 Worldwide Revenue of Approximately $386.6 Million Company Expects to Exceed High End of Previously Provided Fourth Quarter 2021 Non-GAAP Adjusted EBITDA Guidance Company to Present Today at J.P. Morgan Healthcare Conference at 4:30 pm Eastern Time. REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. ...
The EVOKE Study is the first double-blind, pivotal RCT in spinal cord stimulation (SCS) and includes the longest follow-up period of any SCS study with follow-up out to 36 months. ...
Keith Grossman, Chairman, CEO and President of Nevro. "As the only spinal cord stimulation system that is FDA approved to treat PDN, we believe we are uniquely positioned to treat the thousands of patients suffering from the debilitating effects of PDN with a proven non-drug option. ...
The Nalu neurostimulation system is currently FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications. ...
The Nalu neurostimulation system is currently FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) ...
The small size of the mIPG translates into a less invasive procedure with the potential to reduce certain post-implant complications associated with larger incisions to accommodate traditional sized IPGs or battery replacement surgeries associated with IPGs containing implantable batteries. Cleared for the spinal cord stimulation and peripheral ...